|Bid||5.91 x 3300|
|Ask||6.21 x 100|
|Day's range||5.94 - 6.11|
|52-week range||3.95 - 6.67|
|PE ratio (TTM)||N/A|
|Earnings date||6 Aug 2018 - 10 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.33|
Among the companies with shares expected to trade actively in Wednesday's session are Boeing, Ford, American Airlines, Pfizer and Comcast.
BioCryst Pharmaceuticals, Inc. (BCRX) (“BioCryst” or the “Company”), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today provided an update on the Company’s strategic and financial outlook as a standalone company following the recent termination of its merger agreement with Idera Pharmaceuticals, Inc. (IDRA) (“Idera”). Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, said, “We are moving forward executing our standalone strategy with a great deal of confidence in our programs, our pipeline and our ability to drive value for our stockholders. Also, we are on track for a first half of 2019 initiation of a Phase 1 clinical trial for our ALK-2 inhibitor program for treating fibrodysplasia ossificans progressiva, or FOP.
Inc. called off merger plans Tuesday after BioCryst shareholders voted against the proposal, triggering a $6 million penalty to be paid to Idera. Some BioCryst shareholders, including Great Point Partners LLC and RA Capital Management LLC, had publicly objected to the merger plan and noted that they intended to vote against it.
MARKET PULSE Shares of BioCryst Pharmaceuticals Inc. (bcrx) and Idera Pharmaceuticals Inc. (idra) were active in the extended session Tuesday following a brief halt after BioCryst shareholders voted down a merger between the two drug companies.
BioCryst Pharmaceuticals, Inc. (BCRX) (“BioCryst”) today announced that it has terminated the previously announced merger agreement with Idera Pharmaceuticals, Inc. (IDRA) (“Idera”) following the BioCryst stockholders’ failure to approve the adoption of the merger agreement at the BioCryst Special Meeting of Stockholders held today. “We respect and understand the views of our stockholders and are moving forward fully-focused on executing our business plan as a standalone company,” said Jon P. Stonehouse, BioCryst’s President and Chief Executive Officer.
Shares of Idera (IDRA) decline following the failure of a phase II study of its pipeline candidate, IMO-8400, on adult patients with dermatomyositis.
BioCryst Pharmaceuticals, Inc. (BCRX) (“BioCryst” or the “Company”), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today issued an open letter to stockholders in connection with the Company’s Special Meeting of Stockholders to be held on July 10, 2018. BioCryst’s Special Meeting of Stockholders is scheduled for July 10, 2018. The BioCryst Board of Directors believes this transaction represents a significant opportunity to enhance the value of your investment in BioCryst and unanimously recommends that stockholders vote “FOR” the transaction, which will create a new company to be called Valenscion Incorporated (“Valenscion” or the “combined company”).
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 26 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...
BioCryst Pharmaceuticals, Inc. and Idera Pharmaceuticals, Inc. today jointly announced that they have each rescheduled their respective Special Meetings of Stockholders to vote on the proposed merger of BioCryst and Idera to July 10, 2018 at 10:00 AM ET.
BioCryst Pharmaceuticals, Inc. today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the pending merger of BioCryst and Idera.
The Durham, North Carolina-based company said it had a loss of 20 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Shares of BioCryst Pharmaceuticals (BCRX) and Idera Pharmaceuticals (IDRA) plunge following the announcement of their merger.
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 18 cents. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks ...